🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 54903

Found 10 matching trials

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

PHASE1

The objective of the study was to investigate safety, tolerability and phar...

Status

Completed

Location

Multiple Locations

Start Date

2008-06

Trial ID

NCT02221375

Treatments Being Tested

BHT low BHT medium BHT high BI 54903 XX low BI 54903 XX medium 1 BI 54903 XX medium 2 BI 54903 XX high Ciclesonide

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

PHASE2

The aim of this study is to assess and compare efficacy and safety of BI 54...

Status

Withdrawn

Location

Multiple Locations

Start Date

2011-11

Trial ID

NCT01458886

Treatments Being Tested

BI 54903 MD Placebo matching Respimat Placebo matching Respimat BI 54903

Olodaterol Bridging Study in Asthma

PHASE2

The aim of the study is to establish the olodaterol dose in the ethanolic f...

Status

Withdrawn

Location

1249.7.33003 Boehringer Ingelheim Investigational Site

Start Date

2011-10

Trial ID

NCT01428622

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

PHASE1

The primary objective is to compare the systemic exposure to tiotropium and...

Status

Completed

Location

1298.2.1 Boehringer Ingelheim Investigational Site

Start Date

2011-03

Trial ID

NCT01309139

Treatments Being Tested

Tiotropium Tiotropium BI 54903 BI 54903

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

PHASE1

The primary objective of this study was to compare the systemic exposure of...

Status

Completed

Location

Multiple Locations

Start Date

2009-04

Trial ID

NCT02222428

Treatments Being Tested

BI 1744 CL/BI 54903 XX FDC BI 54903 XX BI 1744 CL

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

PHASE1

The primary objective of this study was to compare the systemic exposure of...

Status

Completed

Location

Multiple Locations

Start Date

2009-03

Trial ID

NCT02220660

Treatments Being Tested

BI 1744 CL BI 54903 XX BI 1744 CL + BI 54903 XX FDC Placebo

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

PHASE2

The aim of the study is to assess and compare efficacy and safety of BI 549...

Status

Terminated

Location

1248.5.01047 Boehringer Ingelheim Investigational Site

Start Date

2011-07-21

Trial ID

NCT01397162

Treatments Being Tested

Fluticasone propionate Placebo BI 54903

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

PHASE2

The aim of the study is to assess and compare efficacy and safety of BI 549...

Status

Terminated

Location

1248.7.01047 Boehringer Ingelheim Investigational Site

Start Date

2011-07-01

Trial ID

NCT01396278

Treatments Being Tested

Placebo Fluticasone propionate BI 54903

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

PHASE2

The aim of this study is to assess and compare efficacy and safety of BI 54...

Status

Withdrawn

Location

Multiple Locations

Start Date

2011-11

Trial ID

NCT01458912

Treatments Being Tested

Placebo matching Respimat Placebo matching Respimat BI 54903 MD BI 54903 HD

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

PHASE2

The aim of the study is to assess and compare efficacy and safety of BI 549...

Status

Terminated

Location

1248.6.01047 Boehringer Ingelheim Investigational Site

Start Date

2011-07-01

Trial ID

NCT01397201

Treatments Being Tested

Placebo BI 54903 Fluticasone propionate

Previous Next